Drug Trial Radar · NCT05169515
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
121
Planned (sponsor's estimate)
Start
Oct 26, 2022
Primary completion
Apr 30, 2029
Study completion Apr 30, 2029
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Dec 27, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the safety, efficacy, and pharmacokinetics of mosunetuzumab or glofitamab in combination with CELMoDs (CC-220 and/or CC-99282) in participants with B-cell NHL.
Conditions
- Non-Hodgkin Lymphoma
Interventions
SC MosunetuzumabDrug
Participants will receive SC mosunetuzumab for 12 cycles (cycle length = 21 days or 28 days for Cycle 1 and 28 days for Cycles 2-12)
IV GlofitamabDrug
Participants will receive IV glofitamab for 12 cycles (cycle length = 21 days)
IberdomideDrug
Arm 1: Participants will receive oral CC-220 from Day 1-21 of Cycle 2-12 (cycle length = 28 days for Cycles 2-12)
GolcadomideDrug
Arm 1: Participants will receive oral golcadomide from Day 1-14 starting in either Cycle 1 or Cycle 2 through Cycle 12 (cycle length = 28 days for cycles when golcadomide is to be administered) Arm 2: Participants will receive oral golcadomide from Day 1-10 starting in either Cycle 1, Cycle 2 or Cycle 3 through Cycle 12 (cycle length = 21 days)
ObinutuzumabDrug
Participants in Arm 2 will receive pre-treatment with IV obinutuzumab on Cycle 1 Day 1 (cycle length = 21 days)
TocilizumabDrug
Participants will receive IV tocilizumab as needed to manage cytokine release syndrome (CRS)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of participants with dose-limiting toxicities (DLTs) [dose escalation]Time frame: Until 90 days after the final dose of study treatment
- Percentage of participants with adverse events [all cohorts]Time frame: Until 90 days after the final dose of study treatment
- Best overall response rate (ORR), defined as the proportion of participants whose best overall response is a partial response (PR) or a complete response (CR) during the study, as determined by the investigator using Lugano 2014 criteria [dose expansion]Time frame: Up to 2 years after start of primary study treatment
- Tolerability, as assessed by the incidence of dose interruptions, dose reductions, dose intensity, and treatment discontinuation [dose escalation]Time frame: Until 90 days after the final dose of study treatment
Locations
24 sites in 5 countries. Site status is shown where the registry gives one.
UCSF/Hematology, Blood & Marrow Transplant, And Cellular Therapy (HBC) Program
San Francisco, California
University of Colorado
Aurora, Colorado
Moffitt Cancer Center
Tampa, Florida
The University of Chicago
Chicago, Illinois
Levine Cancer Institute
Charlotte, North Carolina
UT MD Anderson Cancer Center
Houston, Texas
Soroka
Beersheba, Israel
Rambam Health Care Campus
Haifa, Israel
Hadassah University Hospital - Ein Kerem
Jerusalem, Israel
Center Hospital
Ramat Gan, Israel
Sourasky Medical Center
Tel Aviv, Israel
IRCCS Azienda Ospedaliero Universitaria di Bologna
Bologna, Emilia-Romagna, Italy
IRCCS Istituto Romagnolo per lo studio dei tumori "Dino Amadori"
Meldola, Emilia-Romagna, Italy
Azienda Ospedaliero Universitaria Pisana-Ospedale Santa Chia
Pisa, Piedmont, Italy
Hospital Universitari Vall d Hebron
Barcelona, Spain
Clinica Universidad de Navarra-Madrid
Madrid, Spain
Hospital General Universitario Gregorio Maranon
Madrid, Spain
Hosp Universitario Salamanca
Salamanca, Spain
ICO L'Hospitalet
L'Hospitalet de Llobregat, Barcelona, Spain
Hospital Universitario La Fe
Valencia, Valencia, Spain
NHS Greater Glasgow and Clyde
Glasgow, United Kingdom
University College London Hospitals
London, United Kingdom
Nottingham University Hospitals City Campus
Nottingham, United Kingdom
Oxford University Hospitals NHS Trust - Churchill Hospital
Oxford, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.